Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Comment
  • Published:

Benefit Corporation: a path to affordable gene therapies?

Nature Medicine volume 25, pages 1813–1814 (2019)Cite this article

Subjects

With the growing number of efficient gene therapies on the market, now is the time to take actions to ensure reasonable pricing of gene therapy products. Among these, we propose to incentivize gene therapy companies to adopt a status that translates their corporate social responsibility into concrete commitments.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. High, K. A. & Roncarolo, M. G. N. Engl. J. Med. 381, 455–464 (2019).

    Article  Google Scholar 

  2. Marsden G., Towse, A., Pearson, S. D., Dreitlin, B. & Henshall, C. Gene Therapy: Understanding the Science, Assessing the Evidence, and Paying for Value https://icer-review.org/material/white-paper-gene-therapy (2017).

  3. Bach, P. B. ‘Anchoring’ was at work in setting the price of Novartis’ new gene therapy. STAT https://www.statnews.com/2019/06/04/anchoring-price-zolgensma (2019).

  4. Brody, B. The Hastings Center Report 26, 5–11 (1996).

    Article  CAS  Google Scholar 

  5. World Health Organization. Improving the Transparency of Markets for Medicines, Vaccines, and Other Health Products [footnote]. https://apps.who.int/gb/ebwha/pdf_files/WHA72/A72_ACONF2Rev1-en.pdf (2019).

  6. Cummings, B. Columbia Law Rev. 112, 578–627 (2012).

    Google Scholar 

  7. Business Roundtable. Our Commitment. https://opportunity.businessroundtable.org/ourcommitment (2019).

Download references

Author information

Authors and Affiliations

  1. Collège de France, Assistance Publique des Hôpitaux de Paris, Hôpital Necker Enfants Malades, Unité d’Immunologie-Hématologie Pédiatrique, and Imagine Institute, INSERM UMR 1163, Paris, France

    Alain Fischer

  2. Ecares, Solvay Brussels School of Economics and Management, Université libre de Bruxelles, Brussels, Belgium

    Mathias Dewatripont

  3. I3h Institute, Université libre de Bruxelles, Brussels, Belgium

    Mathias Dewatripont & Michel Goldman

Authors
  1. Alain Fischer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mathias Dewatripont
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Michel Goldman
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Alain Fischer or Michel Goldman.

Ethics declarations

Competing interests

The authors declare no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Fischer, A., Dewatripont, M. & Goldman, M. Benefit Corporation: a path to affordable gene therapies?. Nat Med 25, 1813–1814 (2019). https://doi.org/10.1038/s41591-019-0676-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41591-019-0676-z

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing